MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2

Cancer Letters

Volumn 363, Issue 2, 2015, Pages 146-155

  Xu, Ya Fei ^a   Mao, Yan Ping ^a   Li, Ying Qin ^a   Ren, Xian Yue ^a   He, Qing Mei ^a   Tang, Xin Ran ^a   Sun, Ying ^a   Liu, Na ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cell growth; Dab2; Invasion; MiR 93; Nasopharyngeal carcinoma

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 93; UNCLASSIFIED DRUG; DAB2 PROTEIN, HUMAN; MIRN93 MICRORNA, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DAB2 GENE; FEMALE; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; APOPTOSIS; BIOSYNTHESIS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; TUMOR SUPPRESSOR PROTEINS;

EID: 84929264308     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.006     Document Type: Article

References (53)

1. Feng B.J., Huang W., Shugart Y.Y., Lee M.K., Zhang F., Xia J.C., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat. Genet 2002, 31:395-399.
2. Ou S.H., Zell J.A., Ziogas A., Anton-Culver H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann. Oncol 2007, 18:29-35.
3. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol 2002, 12:421-429.
4. Jia W.H., Collins A., Zeng Y.X., Feng B.J., Yu X.J., Huang L.X., et al. Complex segregation analysis of nasopharyngeal carcinoma in Guangdong, China: evidence for a multifactorial mode of inheritance (complex segregation analysis of NPC in China). Eur. J. Hum. Genet 2005, 13:248-252.
5. Xu F.H., Xiong D., Xu Y.F., Cao S.M., Xue W.Q., Qin H.D., et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J. Natl. Cancer Inst 2012, 104:1396-1410.
6. Ma J., Mai H.Q., Hong M.H., Cui N.J., Lu T.X., Lu L.X., et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations?. Int. J. Radiat. Oncol. Biol. Phys 2001, 50:1181-1189.
7. Xiao W.W., Huang S.M., Han F., Wu S.X., Lu L.X., Lin C.G., et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 2011, 117:1874-1883.
8. Lai S.Z., Li W.F., Chen L., Luo W., Chen Y.Y., Liu L.Z., et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int. J. Radiat. Oncol. Biol. Phys 2011, 80:661-668.
9. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet 2004, 5:522-531.
10. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
11. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
12. Esau C., Kang X., Peralta E., Hanson E., Marcusson E.G., Ravichandran L.V., et al. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem 2004, 279:52361-52365.
13. Poy M.N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X., Macdonald P.E., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432:226-230.
14. Liu N., Chen N.Y., Cui R.X., Li W.F., Li Y., Wei R.R., et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012, 13:633-641.
15. Chang Y., Liu C., Yang J., Liu G., Feng F., Tang J., et al. MiR-20a triggers metastasis of gallbladder carcinoma. J. Hepatol 2013, 59:518-527.
16. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
17. Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol 2008, 10:202-210.
18. Lu J., Luo H., Liu X., Peng Y., Zhang B., Wang L., et al. MiR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma. Carcinogenesis 2013, 35:554-563.
19. Lu J., He M.L., Wang L., Chen Y., Liu X., Dong Q., et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011, 71:225-233.
20. Liu N., Tang L.L., Sun Y., Cui R.X., Wang H.Y., Huang B.J., et al. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett 2013, 329:181-188.
21. Zhang L.Y., Ho-Fun Lee V., Wong A.M., Kwong D.L., Zhu Y.H., Dong S.S., et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 2013, 34:454-463.
22. Xia H., Cheung W.K., Sze J., Lu G., Jiang S., Yao H., et al. MiR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J. Biol. Chem 2010, 285:36995-37004.
23. Liu N., Jiang N., Guo R., Jiang W., He Q.M., Xu Y.F., et al. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol. Cancer 2013, 12:123.
24. Yi C., Wang Q., Wang L., Huang Y., Li L., Liu L., et al. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 2012, 31:4421-4433.
25. Fang L., Du W.W., Yang W., Rutnam Z.J., Peng C., Li H., et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle 2012, 11:4352-4365.
26. Yu X.F., Zou J., Bao Z.J., Dong J. MiR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J. Gastroenterol 2011, 17:4711-4717.
27. Liu S., Patel S.H., Ginestier C., Ibarra I., Martin-Trevino R., Bai S., et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 2012, 8:e1002751.
28. Fang L., Deng Z., Shatseva T., Yang J., Peng C., Du W.W., et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2010, 30:806-821.
29. Tang J.F., Yu Z.H., Liu T., Lin Z.Y., Wang Y.H., Yang L.W., et al. Five miRNAs as novel diagnostic biomarker candidates for primary nasopharyngeal carcinoma. Asian Pac. J. Cancer Prev 2014, 15:7575-7581.
30. Li W., Yu C.P., Xia J.T., Zhang L., Weng G.X., Zheng H.Q., et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res 2009, 15:1393-1399.
31. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
32. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human MicroRNA targets. PLoS Biol 2004, 2:e363.
33. Fazili Z., Sun W., Mittelstaedt S., Cohen C., Xu X.X. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999, 18:3104-3113.
34. Hocevar B.A., Prunier C., Howe P.H. Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J. Biol. Chem 2005, 280:25920-25927.
35. Lyu X., Fang W., Cai L., Zheng H., Ye Y., Zhang L., et al. TGFbetaR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol. Cancer 2014, 13:51.
36. Petrocca F., Visone R., Onelli M.R., Shah M.H., Nicoloso M.S., de Martino I., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
37. Du L., Zhao Z., Ma X., Hsiao T.H., Chen Y., Young E., et al. MiR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene 2013, 33:4307-4315.
38. Li Y., Tan W., Neo T.W., Aung M.O., Wasser S., Lim S.G., et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009, 100:1234-1242.
39. Mok S.C., Chan W.Y., Wong K.K., Cheung K.K., Lau C.C., Ng S.W., et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998, 16:2381-2387.
40. Bagadi S.A., Prasad C.P., Srivastava A., Prashad R., Gupta S.D., Ralhan R. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res. Treat 2007, 104:277-286.
41. Tseng C.P., Ely B.D., Li Y., Pong R.C., Hsieh J.T. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 1998, 139:3542-3553.
42. Anupam K., Tusharkant C., Gupta S.D., Ranju R. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J. Gastroenterol 2006, 12:6041-6045.
43. Tong J.H., Ng D.C., Chau S.L., So K.K., Leung P.P., Lee T.L., et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010, 10:253.
44. Yan Z.X., Wu L.L., Xue K., Zhang Q.L., Guo Y., Romero M., et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 2014, 28:880-887.
45. Chao A., Lin C.Y., Lee Y.S., Tsai C.L., Wei P.C., Hsueh S., et al. Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene 2011, 31:764-775.
46. Wang Z., Tseng C.P., Pong R.C., Chen H., McConnell J.D., Navone N., et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J. Biol. Chem 2002, 277:12622-12631.
47. He J., Smith E.R., Xu X.X. Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. J. Biol. Chem 2001, 276:26814-26818.
48. Martin J.C., Herbert B.S., Hocevar B.A. Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br. J. Cancer 2010, 103:1716-1723.
49. Prunier C., Howe P.H. Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J. Biol. Chem 2005, 280:17540-17548.
50. Cho W.C. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin. Ther. Targets 2012, 16:747-759.
51. Cho W.C. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol 2010, 42:1273-1281.
52. Cho W.C. MicroRNAs in cancer - from research to therapy. Biochim. Biophys. Acta 2010, 1805:209-217.
53. Garzon R., Marcucci G. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr. Opin. Oncol 2012, 24:655-659.